Pillar Biosciences Stock

Pillar Biosciences specializes in sequencing technology platform and proprietary data analysis toolkit.

Sign up today and learn more about Pillar Biosciences Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Pillar Biosciences Stock

Pillar Biosciences is prized with its patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which achieves high sensitivity and specificity with clinical samples. The platform provides a fast, simple and affordable targeted sequencing method for NGS-based oncology testing. The start-up has also released its beta version of Lung & Colon Cancer Somatic Mutation Panel and BRCA1 & BRCA2 Germline Mutation Panel to cancer centers and clinical testing companies in the US and China for validation studies. The company was founded in 2014 and is headquartered in Natick, Massachusetts.

Funding History

August 2014$2.9M
May 2016$18.0M
November 2018$16.0M
February 2020$32.4M
May 2021$90.0M


Founder & CEO

Gang Song

Co-Founder and Chief Science Officer

Zhaohui Wang

Chief Operating Officer

Martin Zillmann

Chief Financial Officer

Vincent Ricci

Chief Executive Officer

Randy Pritchard

General Counsel

Christa Adkins

Interim CFO

Richard P. Shea

Chief Commercial Officer

Dan Harma


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: